News
-
Gerresheimer will spend €12m to add approximately 5,000 sq. meters to the plastics production area at its manufacturing facility in Horsovsky Tyn, Czech Republic. The plant produces medical plastic devices, including insulin pens and inhalers.… Read more . . .
-
The Committee for Medicinal Products for Human Use (CHMP) has recommended against granting a marketing authorization to Pharmaxis’s Bronchitol inhaled dry powder mannitol formulation for the treatment of cystic fibrosis. The CHMP had previously indicated… Read more . . .
-
According to news reports, Pfizer has reversed its position on the closure of its R&D facility at Sandwich, UK, saving 350 jobs. The company’s inhalation R&D group has operated out of Sandwich and had been… Read more . . .
-
A study of COPD patients by researchers from Johhs Hopkins found that use of inhaled corticosteroids for six months increased the risk of bone fracture by 27%. The researchers reviewed data from both double-blind and… Read more . . .
-
An intranasal formulation of diazepam being developed by Neurelis for the treatment of acute seizures outside of a hospital setting demonstrated 96% bioavailability compared to the only currently approved treatment, a rectal diazepam gel. The… Read more . . .
-
The Pulmonary & Nasal laboratory Scientist team at Catalent is responsible for the support of pharmaceutical product development in a range of dosage forms both directly with customers and in collaboration with other Catalent facilities.… Read more . . .
-
Massacheusetts biotech company is introducing a new dry powder delivery platform based on its iSPERSE cationic salt formulations at ISAM 2011. According to the company, the iSPERSE platform “enables inhaled delivery of high drug loads,… Read more . . .
-
In an effort to continue their leading status of innovation and development, through Four Corners Group, Trudell Medical International is now seeking a Group Director, Science & Technology. THE ROLE This position will be responsible… Read more . . .
-
A Phase 2b study of Aradigm’s inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchietasis has shown a significant reduction in Pseudomonas aeruginosa colony forming units per gram of sputum (CFUs) over a 28-day treatment… Read more . . .
-
Pearl Therapeutics is advancing its PT003 combination inhaler for COPD, and the products individual components, into a new series of Phase 2 trials in patients with moderate-to-severe COPD. The individual compounds are PT001, glycopyrrolate, and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan